Work

Abstract 5515: ELVN-001, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia alone or in combination with asciminib

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-5515

Authors: Stefan David Gross, Christopher A. Eide, Michael R. Burkard, Anna Reister Schultz, Yiheng Zhang, Joseph E. Aslan, Owen J. McCarty, Monette A. Aujay, Samuel Kintz, Brian J. Druker, Joseph P. Lyssikatos

Institution: Oregon Health & Science University

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409640800

Cites:

Cited by: 1

Related to: 10